TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01535430

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain mapping
Description: Brain mapping will be employed pre-, intra-, and post-operatively to evaluate specific functions.
Study: NCT04134325

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab administered at 240mg every two weeks or 480 mg every four weeks as per standard of care after treatment with CD30.CAR T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab administered at 240mg every two weeks or 480 mg every four weeks as per standard of care after treatment with CD30.CAR T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered at 200 mg every three weeks or 400 mg every six weeks as per standard of care after treatment with CD30.CAR T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered at 200 mg every three weeks or 400 mg every six weeks as per standard of care after treatment with CD30.CAR T cells
Study: NCT02026622

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Description: ASL, rest f-MRI, FLAIR, white matter hyper intensities load

Intervention type: DEVICE
Group type: OTHER
Intervention: transcranial doppler and TPI
Description: transcranial doppler TPI

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: explicitative interview
Study: NCT02577406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-221
Description: Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BSC
Description: Best supportive care includes, hydroxyurea for leukocytosis and/or differentiation-like syndrome, anti-infectives, analgesics, antiemetics, antipyretics, transfusions and nutritional support

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BSC
Description: Best supportive care includes, hydroxyurea for leukocytosis and/or differentiation-like syndrome, anti-infectives, analgesics, antiemetics, antipyretics, transfusions and nutritional support

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: continuous 28-day cycles of azacitidine 75 mg/m2/day SC for 7 days, plus BSC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose cytarabine (LDAC)
Description: continuous 28-day cycles of cytarabine 20 mg SC twice a day (BID) for 10 days, plus BSC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermediate-dose cytarabine (IDAC)
Description: 28-day cycles of cytarabine 0.5 to 1.5 g/m2/day IV for 3 to 6 days, per standard institutional practice, plus BSC; only BSC given after IDAC therapy concludes per standard institutional practice
Study: NCT02998437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole 10mg
Description: Period 1: Ilaprazole 10mg, one a day, one day Period 2: Ilaprazole 10mg, twice a day, 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500mg
Description: Period 1: Clarithromycin 500mg 1 tab., twice a day, one day Period 2: Clarithromycin 500mg 1 tab., one a day at 5 day
Study: NCT01110044

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix™
Description: Intramuscular, four doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix™
Description: Oral, two doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix™
Description: Oral, two doses
Study: NCT02998437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 500 Mg
Description: Period 1: Amoxicillin 500mg 2 cap., one a day, one day Period 2: Amoxicillin 500mg 2 cap., one a day at 5 day
Study: NCT03947164

Intervention type: OTHER
Group type: OTHER
Intervention: biopsy
Description: For cases and controls, before the intervention : a questioning, clinical symptoms of POPs and urinary incontinence, a detailed clinical examination, and an urodynamic assessment (in case of POPs) and an ultrasound guided MEA biopsy.~Patients will be seen on post-operative visits between 15 days and 2 months after surgery for an examination and clinical examination.

Intervention type: OTHER
Group type: OTHER
Intervention: biopsy
Description: For cases and controls, before the intervention : a questioning, clinical symptoms of POPs and urinary incontinence, a detailed clinical examination, and an urodynamic assessment (in case of POPs) and an ultrasound guided MEA biopsy.~Patients will be seen on post-operative visits between 15 days and 2 months after surgery for an examination and clinical examination.
Study: NCT04666454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: Adenosine infusion 70 µg/kg/min for 3 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyridamole 200 mg
Description: 200 mg b.i.d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban 5 mg Oral Tablet
Description: 5mg b.i.d

Intervention type: OTHER
Group type: OTHER
Intervention: Care as recommended by the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology for takotsubo syndrome
Description: This treatment will vary depending on local routines and the degree of adherence to the recommendations.
Study: NCT03158948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nangibotide 0.3 mg/kg
Description: Formulated LR12 peptide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nangibotide 1 mg/kg
Description: Formulated LR12 peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nangibotide 3 mg/kg
Description: Formulated LR12 peptide
Study: NCT03919617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REMD-477
Description: 4-Week, open-label, once weekly subcutaneous injection with 70mg REMD-477.
Study: NCT02652234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Endostar, ih, QD，day 1 of cycle 1; Endostar, ih, QD，day 2-15 of cycle 3;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Study: NCT04513028

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-Glucan
Description: 500mg (1 capsule) by mouth twice a day for 21 days.
Study: NCT02072005

Intervention type: OTHER
Intervention: mSMART smartphone application
Description: This application is an interface that provides subjects with information and questionnaires related to their medication.
Study: NCT04511663

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Assertive community treatment
Description: The intervention team consisted of psychiatrists, nurses, clinical psychologists, social workers, rehabilitation teachers. The specific services provided by the team include individual service plan. Each patient got a comprehensive evaluation within one month to establish treatment goals and individual intervention plan, rehabilitation training, family intervention peer support group, individual psychological counseling and crisis intervention.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Basic public health services.
Description: The control group received regular medical follow-up including symptom and medication evaluation, social function evaluation and physical examination after hospital discharge. The frequency was once a quarter.
Study: NCT01898676

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex Sodium Extended-release 250mg
Description: Two tablets of Divalproex Sodium Extended-Release 250mg will be given to the subject in two treatment periods

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex Sodium Extended-release 250mg
Description: Two tablets of Divalproex Sodium Extended-Release 250mg will be given to the subject in two treatment periods

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DEPAKOTE 250mg
Description: Two tablets of DEPAKOTE 250mg will be given to the subject in two treatment periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DEPAKOTE 250mg
Description: Two tablets of DEPAKOTE 250mg will be given to the subject in two treatment periods.
Study: NCT06629974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental empowerment program
Description: The empowerment program consisted of two parts: the empowerment training program for parents and motivational interviews.~The empowerment training program was prepared to enable parents to carry out the care process more effectively in areas where parents have difficulties caring for their children with autism. Within the scope of the empowerment training program, parents were trained on the importance of play and communication, problems and management in the field of nutrition, sleep problems and management, safety and protection from accidents, and problems and management in the field of self-care.~Ten days after the empowerment training program, two face-to-face motivational interviews were conducted with each participant in the intervention group. Each participant had a one-week break between the first and second motivational interviews. Each motivational interview session lasted approximately 25-30 minutes.
Study: NCT02728271

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPC cell infusion
Description: Administration of total lymphatic irradiation, antithymocyte globulins, and high dose cyclophosphamide, followed by the infusion of autologous stem cells.~Patients will not receive any cyclosporin A, rituximab, or azathioprine post transplant.
Study: NCT01895140

Intervention type: DEVICE
Group type: OTHER
Intervention: Renal denervation device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation device
Study: NCT04833192

Intervention type: DIAGNOSTIC_TEST
Intervention: experimental group
Description: DHEAS.24h-UFC,ACTH and cortisol are measured in the experimental group
Study: NCT01554592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withdrawal of statin therapy
Description: Participants currently received statin therapy will have their statin stopped for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin therapy
Description: Participants will continue on stable statin therapy.
Study: NCT01841827

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03273530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Supported Employment
Description: vocational assessment followed by job placement and on-going work-related social skills revision and reinforcement
Study: NCT01255033

Intervention type: DEVICE
Intervention: Monitoring of tissular oxygenation
Description: Equanox: cerebral oxygenation by spectroscopy, near-infrared through forehead and noninvasive devices~Inspectra: tissular oxygenation by spectroscopy, near-infrared through thenar and noninvasive device
Study: NCT01934946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: comprehensive rehabilitation
Description: received 14 days hospitalization for comprehensive rehabilitation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: home rehabilitation
Description: 6 times home rehabilitation services within 3 months
Study: NCT00550121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin C

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03423394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Description: The MET intervention will consist of three 45-90 minute telephone delivered sessions that will be staggered to occur 1 week, 1 month, and 2 months after the baseline assessment. The first MET session intervention will involve a counselor using motivational interviewing (MI) strategies to establish an empathic therapeutic relationship and focus learning about the PTSD symptoms the participant is experiencing and exploring ambivalence about seeking treatment services. MET sessions 2 and 3 will focus on identifying and responding to risk factors for dropping out of treatment (increases in ambivalence, avoidance behavior, concerns about stigma, life chaos), identifying and responding to barriers to participant's active engagement in treatment, and facilitating enrollment in alternate therapeutic resources if necessary.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: TAU will include a written referral list comprised of PTSD resources including information on in-person treatments, self-help, web-based and bibliotherapy options. At the completion of the study, participants in the TAU condition will be offered the MET intervention.
Study: NCT01016106

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Buccal Swab
Description: During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT laboratories in Lenexa, Kansas.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Buccal Swab
Description: During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT laboratories in Lenexa, Kansas.
Study: NCT05276713

Intervention type: DRUG
Intervention: Tucidinostat
Description: Tucidinostat in combination with endocrine drugs
Study: NCT01328431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Intervention with NRT Initiation
Description: Brief Negotiated Interview is a manual-guided therapy designed for the ED setting. The purpose is to assist subjects to change some aspect of their smoking and to decide to start nicotine replacement therapy while in the ED. It combines techniques from motivational interviewing and stages of change. a 6-week supply of nicotine replacement therapy is given in the form of patches and gum and subjects are encouraged to use both concurrently. Patches come in 21 mg, 14 mg, and 7 mg doses and the dosage is determined based on how many cigarettes per day a subject is smoking. All subjects receive 400 pieces of 2 mg nicotine gum. All subjects complete a referral form for the state's Smokers' Quitline which is then faxed directly to the Quitline's vendor.
Study: NCT04072146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mg
Description: Cross over bioavailability study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mg
Description: Cross over bioavailability study
Study: NCT02770040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: INFLIXIMAB (REMICADE) in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution and infused

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: INFLIXIMAB (REMICADE) in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution and infused

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: INFLIXIMAB (REMICADE) in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution and infused
Study: NCT01211665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: In intravenous form (for a daily dose of 1 g/day on treatment days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: In intravenous form (for a daily dose of 1 g/day on treatment days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral prednisolone used as a taper, with suggested dosages starting at 80 mg and tapering to 5 mg.
Study: NCT04211402

Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study
Study: NCT00575991

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid
Description: 3 grams per day of 80% CLA in safflower oil (2.4 grams active CLA isomers in triglyceride form)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Conjugated linoleic acid
Description: 3 grams per day of 80% CLA in safflower oil (2.4 grams active CLA isomers in triglyceride form)
Study: NCT00985478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV342
Description: 25 mg once daily - Maximal Tolerated Dose
Study: NCT02511704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Multiple dose nicotine
Study: NCT00985478

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo
Study: NCT02390908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate PLUS intervention
Description: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate PLUS intervention
Description: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate PLUS intervention
Description: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list PLUS intervention
Description: In addition to treatment as usual, participants will receive handouts with printed information about HIV, the importance of ART adherence, and problematic alcohol use and HIV disease progression. Following their assessment 12 months after their baseline visit, participants will receive the PLUS intervention.
Study: NCT03810807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Dose level 1 Dacomitinib, Dose level 2 Dacomitinib, Dose level 3 Dacomitinib. Three patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (28 days for cycle 1) before dose escalation decision is made.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Dose level 1, 2 and 3 Osimertinib 40mg daily. Three patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (28 days for cycle 1) before dose escalation decision is made.
Study: NCT02829073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromonics Tinnitus Treatment Program
Description: The Neuromonics Oasis™ treatment device will be fit to individuals reporting significant tinnitus. Assessment of primary and secondary measures will be made at 0 and 6 months following fitting.
Study: NCT02511704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Multiple dose nicotine
Study: NCT04282902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pirfenidone
Description: Pirfenidone is administered orally 3 times a day, 2 tablets each time, for a period of 4 weeks or longer
Study: NCT01805856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPC piperacillin sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEZ, cefazolin sodium
Study: NCT03728725

Intervention type: DEVICE
Intervention: Cepheid Gene Xpert MTB/XDR
Description: The Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA) is an integrated, automated, cartridge-based system for MDR-TB diagnosis that uses the GeneXpert instrument platform. WHO confirmed evidence to support the widespread use of the Xpert MTB/RIF assay in 2010 and the assay has since been widely used in TB programs, but it is only capable of identifying Mycobacterium tuberculosis (Mtb) and detecting RIF resistance. The Xpert MTB/XDR assay will be evaluated for INH and second-line resistance detection, and to recommend its use in diverse clinical settings. The focus of this protocol is the multicentre clinical evaluation.

Intervention type: DEVICE
Intervention: Cepheid Gene Xpert MTB/XDR
Description: The Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA) is an integrated, automated, cartridge-based system for MDR-TB diagnosis that uses the GeneXpert instrument platform. WHO confirmed evidence to support the widespread use of the Xpert MTB/RIF assay in 2010 and the assay has since been widely used in TB programs, but it is only capable of identifying Mycobacterium tuberculosis (Mtb) and detecting RIF resistance. The Xpert MTB/XDR assay will be evaluated for INH and second-line resistance detection, and to recommend its use in diverse clinical settings. The focus of this protocol is the multicentre clinical evaluation.
Study: NCT03970811

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate Implants
Description: dental implants are immediately placed after tooth extraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Implants
Description: dental implants are immediately placed after tooth extraction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: temporary restoration
Description: temporary restoration will be placed immediately after implant placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: final restoration
Description: final restoration (loading) will be placed 3 months postsurgical

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: final restoration
Description: final restoration (loading) will be placed 3 months postsurgical
Study: NCT00567879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Participants received escalating doses of panobinostat until the maximum tolerated dose (MTD) was reached. The starting dose of panobinostat i.v. was 10mg/m\^2 at days 1 and 8 during a 21-day treatment cycle. The oral panobinostat starting dose was 20 mg twice weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Fixed doses of trastuzumab were given in parallel with panobinostat. Trastuzumab i.v. was given weekly according to the instruction in the package insert.